Q-omics provides the consensus-scored GTF2IRD1P1 profile across patient tissues and cancer cell-line models. GTF2IRD1P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GTF2IRD1P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GTF2IRD1P1 RNA expression shows 16,367 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where GTF2IRD1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2IRD1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2IRD1P1 survival associations across molecular data types. GTF2IRD1P1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2IRD1P1 RNA expression–survival associations across cancer types. High GTF2IRD1P1 expression shows unfavorable associations in UVM, KICH, COAD, BLCA and LGG, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for GTF2IRD1P1 RNA expression.
This table summarizes GTF2IRD1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2IRD1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2IRD1P1 shows lower tumor expression in KIRC and higher tumor expression in LUSC, COAD, LIHC, LUAD and BRCA. The KIRC box plot shows higher GTF2IRD1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p < 0.001).
This table shows molecular features associated with GTF2IRD1P1 in patient tissues and cancer cell lines. In patient samples, GTF2IRD1P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2IRD1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
